Here, we demonstrated that MAEL negatively regulated ILKAP protein levels by promoting its lysosome-dependent degradation in GC cells, while treatment with the proteasome inhibitor MG132 has no significant effect on the MAEL-mediated degradation of ILKAP protein (Figure 5F and Supplementary Figure 7). Here, MAEL is linked to gastric cancer.